PROPOXYPHENE suppliers

Melting point:

75-76°

alpha 

D25 +67.3° (c = 0.6 in chloroform)

Boiling point:

475.43°C (rough estimate)

Density 

1.0751 (rough estimate)

refractive index 

1.5614 (estimate)

Flash point:

2℃

storage temp. 

2-8°C

pka

pKa 6.3(50% aq EtOH) (Uncertain)

Symbol(GHS) 

GHS02,GHS07

Signal word 

Danger

Hazard statements 

H225-H302+H312+H332-H319

Precautionary statements 

P210-P261-P302+P352+P312-P304+P340+P312-P337+P313-P403+P235

Hazard Codes 

F,Xn,T

Risk Statements 

11-20/21/22-36-52/53-25

Safety Statements 

16-26-36/37-61-45-36/37/39

RIDADR 

3249

WGK Germany 

2

HazardClass 

6.1(b)

PackingGroup 

III

Toxicity

An opioid analgesic similar in structure to methadone. It is a much less potent analgesic than morphine and is devoid of antipyretic or anti-inflammatory effects. Its side effects are qualitatively similar to codeine. The clinical indications for propoxyphene are much the same as for aspirin. It is used when the degree of analgesia required is less than that produced by morphine. Recent clinical trials suggest that propoxyphene is no more effective in controlling mild pain than is aspirin. Because they act by different mechanisms, aspirin and propoxyphene have often been given in combination. Recently, there has been a trend away from use of propoxyphene because its weak analgesic properties do not compensate for other problems with its use. Interestingly, the analgesic activity of propoxyphene resides largely in the dextrorotatory isomer, whereas the antitussive effect is produced primarily by the levorotatory isomer. The use of propoxyphene was banned in the United States in November 2010. The oral LD50 in rats is 84 mg/kg.